Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematotoxicity01.05.01.007; 12.03.01.025--Not Available
Infestation11.09.01.001; 23.11.01.002--Not Available
Limb discomfort15.03.04.0140.008584%Not Available
Jaw disorder15.02.04.0090.001495%Not Available
Joint lock15.01.08.0040.000940%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Paraproteinaemia16.23.01.001; 01.14.01.0010.000530%Not Available
Spinal cord disorder17.10.01.0100.000241%Not Available
Spinal disorder15.02.04.0230.003400%Not Available
Spondylitis15.01.09.0020.001181%Not Available
Cardiac valve disease02.07.02.0010.001929%Not Available
White blood cell disorder01.02.05.0020.003641%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal neoplasm20.01.04.004; 16.08.03.0010.000362%Not Available
Intervertebral disc disorder15.10.01.0030.001350%Not Available
Inner ear disorder04.04.02.0020.000820%Not Available
Mitral valve disease02.07.01.0030.000241%
Ulcer haemorrhage24.07.01.040; 08.03.06.0030.000723%Not Available
Blood disorder01.05.01.0040.002483%Not Available
Immunodeficiency10.03.02.0020.004750%Not Available
Respiratory syncytial virus infection22.07.02.002; 11.05.13.001--Not Available
Adverse drug reaction08.06.01.0090.137868%Not Available
Bone lesion15.02.04.0160.003496%Not Available
Bone marrow disorder01.05.01.0060.001471%Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.0130.133239%Not Available
Gastric neoplasm16.13.11.003; 07.21.04.0060.000241%Not Available
Hepatobiliary disease09.01.08.003--Not Available
The 13th Page    First    Pre   13 14 15 16    Next   Last    Total 16 Pages